Results for this period
Interim period (second quarter)1 April 2026 to 30 September 2026ConsolidatedJapanese GAAPThe width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
Despite a decline in overseas pharmaceuticals, growth in the LAL business and other operations increased revenue. The operating loss widened due to higher manufacturing costs and R&D expenses, while ordinary profit increased due to the sale of investment securities and other factors. An interim net loss was recorded due to higher tax expenses associated with the reversal of deferred tax assets.
None
| Item | Details |
|---|---|
| Fiscal Period Classification | Interim period (second quarter) |
| Accounting standards | Japanese GAAP |
| Consolidated / non-consolidated | Consolidated |
| Period Covered | 1 April 2026 to 30 September 2026 |
| Net Sales | 18,219 Millions of yen (YoY +1.7%) |
| Operating profit | -1,415 Millions of yen |
| Ordinary income | 602 Millions of yen (YoY +13.4%) |
| Profit attributable to owners of the parent | -1,221 Millions of yen |
| Net income per share | -¥22.36 |
| Equity ratio | End of the current fiscal period 85.8 / End of previous period 87.2 |
| Total assets | 84,503 Millions of yen |
| Net assets | 72,504 Millions of yen |
| Full-year earnings forecast | Net Sales 37,100 Millions of yen (YoY +1.2%) / Operating profit -2,900 Millions of yen / Ordinary income -650 Millions of yen / Net income -2,700 Millions of yen |
| Annual Dividend Forecast | 30 Yen → 20 Yen（-33.3%） |
| Segment revenue | Pharmaceuticals 11,441 Millions of yen (YoY -5.7%) / LAL 6,778 Millions of yen (YoY +17.3%) |
| Segment profit | Pharmaceuticals -1,881 Millions of yen / LAL 465 Millions of yen |
| Impairment loss | Not recognized during the interim period |
| Breakdown of extraordinary income (loss) | No extraordinary income or extraordinary loss was recognized during the interim period |
| Disclosure regarding the going concern assumption | None |
| Change in accounting policy | Changes due to revisions to standards No / Other changes No / Change in accounting estimate No / Restatement No |
| Changes in the scope of consolidation | New Not disclosed / Excluded Not disclosed / Notes Material changes in the scope of consolidation during the interim period: None |
| Availability of Supplementary Financial Results Materials | Yes |
| Availability of Financial Results Briefing | Yes (for analysts and institutional investors) |
| Issued Shares at Period-End | 56,814,093 |
| Treasury Shares at Period-End | 2,188,997 |
| Factors Behind Changes in Business Performance | Despite a decline in overseas pharmaceuticals, growth in the LAL business and other operations increased revenue. The operating loss widened due to higher manufacturing costs and R&D expenses, while ordinary profit increased due to the sale of investment securities and other factors. An interim net loss was recorded due to higher tax expenses associated with the reversal of deferred tax assets. |
Items this document does not state (12)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Revenue increased due to growth in the LAL business and other operations, despite a decline in overseas pharmaceuticals. The wider operating loss was attributable to higher manufacturing costs and R&D expenses, the increase in ordinary profit to the sale of investment securities and other factors, and the recognition of an interim net loss attributable to owners of the parent to higher tax expenses associated with the reversal of deferred tax assets.